Preview

Современная ревматология

Расширенный поиск

Проблемы профилактики и лечения глюкокортикоидного остеопороза

https://doi.org/10.14412/1996-7012-2010-610

Полный текст:

Аннотация

Остеопороз (ОП) является серьезной проблемой для больных, длительно принимающих глюкокортикоиды. За последние 20 лет накоплено большое количество знаний об эпидемиологии заболевания, появились препараты с доказанной эффективностью для его профилактики и лечения. Однако большое количество исследований свидетельствует о серьезных недостатках в помощи больным глюкокортикоидным ОП, что требует действенных мер для приведения реального уровня его профилактики и лечения в соответствие требованиям современных клинических рекомендаций

Об авторе

И. А. Баранова



Литература

1. <div><p>Walsh L.J., Wong C., Pringle M. et al. Use of oral glucocorticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313: 344-6.</p><p>LoCascoi V., Bonucci E., Imbimbo B. et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990; 8: 39-51.</p><p>Buckley L.M., Leibs E.S., Cartularo K.S. et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1055-9.</p><p>Laan R.F., van Riel P.L., van de Putte L.D. et al. Low dosw prednisone induced rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993; 119: 963-8.</p><p>Van Staa T.P., Leufkens H.G.M., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-87.</p><p>Van Staa T.P., Leufkens H.G.M., Abenhaim L. et al. Use of oral corticosteroids in the United Kingdom. Q J Med 2000; 93: 105-11.</p><p>Kanis J.A., Johansson H., Oden A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19(6): 893-9.</p><p>Steinbuch M., Youket E.T., Cohen S. Oral glucocorticoid use in associated with increased of fracture. Osteoporosis Int 2004; 15: 323-8.</p><p>Van Staa T.P., Leufkens H.G.M., Abenhaim L. et al. Fractures and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 2000; 39: 1383-9.</p><p>Luengo M., Picado C., Delrio L. et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis - a comparative study. Thorax 1991; 46: 803-6.</p><p>Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis American college of rheumatology task force on osteoporosis guidelines. Arthr Rheum 1996; 39(11): 1791-801.</p><p>Osteoporosis: prevention and treatment. Guidelines for clinical care. University of Michigan Health System 2005. &lt;http://cme.med.umich.edu/pdf/guideline/osteo&gt; porosis05.pdf</p><p>Kelly J.P., Kaufman D.W., Rosenberg L. et al. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005; 14: 837-42.</p><p>Cohen S., Levy R.M., Keller M. et al. Risedronate therapy prevents corticosteroid- induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthr Rheum 1999; 42(11): 2309-18.</p><p>Saag K.G., Emkey R., Schnitzer T.J. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-9.</p><p>Adachi J.D., Saag K.J., Delmas P.D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthr Rheum 2001; 44(1): 202-11.</p><p>Amin S., Lavalley M.P., Simms R.W., Felson D.T. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17(8): 1512-26.</p><p>Van Staa T., Leufkens H.G.M., Abenhaim L. et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.</p><p>Recommendation for the prevention and treatment of glucocorticoid-induced osteoporosis American college of rheumatology task force on osteoporosis guidelines. Arthr Rheum 2201; 44(7): 1496-503.</p><p>clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(Suppl. 10):S1-S34.</p><p>Glucocorticoid-induced osteoporosis. A concise guide to prevention and treatment. Bone and Tooth Society, National Osteoporosis Society, Royal College of Phisicians of London. - www.relondon.ac.uk &lt;http://www.relondon.ac.uk&gt;</p><p>Клинические рекомендации Российской ассоциации по остеопорозу. Остеопороз. Диагностика, профилактика и лечение. Под ред. Л.И. Беневоленской, О.М. Лесняк. М.: ГЭОТАР-Медиа, 2005.</p><p>Клинические рекомендации Российской ассоциации по остеопорозу. Остеопороз. Диагностика, профилактика и лечение. Под ред О.М. Лесняк, Л.И. Беневоленской. М.: ГЭОТАР-Медиа, 2009.</p><p>Geusens P.P., de Nijs R.N., Laan R.F. et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004; 63: 324-5.</p><p>Weinstein M.C. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24(11): 1043-53.</p><p>Kanis J.A., Stevenson M., McCloskey E.V. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007; 11(7):iii-iv, ix-xi, 1-231.</p><p>Van Staa T.P., Geusens P., Zhang B. et al. Individual fracture risk and the costeffectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatol (Oxford) 2007; 46(3): 460-6.</p><p>Beukelman T., Saag K.G., Curtis J.R. et al. Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 2009 Nov 24 [Epub ahead of print].</p><p>Saag K.G., Gehlbach S.H., Curtis J.R. et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 2006; 33: 1651-7.</p><p>Chantler I.W., Davie M.W., Evans S.F. et al. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003; 62: 350-2.</p><p>Yood R.A., Harrold L.R., Fish L. et al. Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 2001; 161: 1322-7.</p><p>Ettinger B., Chidambaran P., Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001; 7: 597-605.</p><p>Mudano A., Allison J., Hill J. et al. Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 2001; 28: 1298-305.</p><p>Blalock S.J., Norton L.L., Patel R.A. et al. Patient knowledge, beliefs, and behavior concerning the prevention and treatment of gluco- corticoid-induced osteoporosis. Arthr Rheum 2005; 53(5): 732-9.</p><p>Walker-Bone K., Wood A., Hull R. et al. The prevention and treatment of glucocorticoid- induced osteoporosis in clinical practice. Clin Med 2004; 4(5): 431-6.</p><p>Sadat-Ali M., Alelq A.H., Alshafei B.A. et al. Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy. Ann Saudi Med 2009; 29(3): 215-8.</p><p>Curtis J.R., Westfall A.O., Allison J.J. et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthr Rheum 2005; 52(8): 2485-94.</p><p>Solomon D.H., Katz J.N., Jacobs J.P. et al. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthr Rheum 2002 Dec; 46(12): 3136-42.</p><p>Liu R.H., Albrecht J., Werth V.P. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006; 142(1): 37-41.</p><p>Wall E., Walker-Bone K. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology. QJM 2008; 101(4): 317-23.</p><p>Chitre M.M., Hayes W. 3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in health plan. J Manag Care Pharm 2008; 14(3): 281-90.</p><p>Ledwich L.J., Clarke K. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multi- specialty practice. J Clin Rheumatol 2009; 15(2): 61-4.</p><p>Guzman-Clark J.R., Fang M.A., Sehl M.E. et al. Barriers in the management of glucocorticoid-induced osteoporosis. Arthr Rheum 2007; 57(1): 140-6.</p><p>Frame P.S. Health maintenance in clinical practice: strategies and barriers. Am Fam Physician 1992; 45: 1192-200.</p><p>Redelmeier D.A., Tan S.H., Booth G.L. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338: 1516-20.</p><p>Ettinger B., Pressman B., Shah H.A. Who bears responsibility for glucocorticoid-exposed patients in a large health maintenance organization? J Manag Care Pharm 2001; 7: 228-32.</p><p>Dolan A.L., Koshy E., Waker M. et al. Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 2004; 63: 183-6.</p></div><br />


Для цитирования:


Баранова И.А. Проблемы профилактики и лечения глюкокортикоидного остеопороза. Современная ревматология. 2010;4(2):94-99. https://doi.org/10.14412/1996-7012-2010-610

For citation:


Baranova I.A. GLUCOCORTICOID-INDUCED OSTEOPOROSIS: PATHOGENESIS, PREVENTION, TREATMENT. Modern Rheumatology Journal. 2010;4(2):94-99. (In Russ.) https://doi.org/10.14412/1996-7012-2010-610

Просмотров: 701


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)